Manufacture of T cells using the Sleeping Beauty system to enforce expression of a CD19-specific chimeric antigen receptor
Authors:
- 16 January 2015
- journal article
- review article
- Published by Springer Nature in Cancer Gene Therapy
- Vol. 22 (2) , 95-100
Abstract
T cells can be reprogrammed to redirect specificity to tumor-associated antigens (TAAs) through the enforced expression of chimeric antigen receptors (CARs). The prototypical CAR is a single-chain molecule that docks with TAA expressed on the cell surface and, in contrast to the T-cell receptor complex, recognizes target cells independent of human leukocyte antigen. The bioprocessing to generate CAR+ T cells has been reduced to clinical practice based on two common steps that are accomplished in compliance with current good manufacturing practice. These are (1) gene transfer to stably integrate the CAR using viral and nonviral approaches and (2) activating the T cells for proliferation by crosslinking CD3 or antigen-driven numeric expansion using activating and propagating cells (AaPCs). Here, we outline our approach to nonviral gene transfer using the Sleeping Beauty system and the selective propagation of CD19-specific CAR+ T cells on AaPCs.Keywords
This publication has 56 references indexed in Scilit:
- Manufacture of Clinical-Grade CD19-Specific T Cells Stably Expressing Chimeric Antigen Receptor Using Sleeping Beauty System and Artificial Antigen Presenting CellsPLOS ONE, 2013
- Infusing CD19-Directed T Cells to Augment Disease Control in Patients Undergoing Autologous Hematopoietic Stem-Cell Transplantation for Advanced B-Lymphoid MalignanciesHuman Gene Therapy, 2012
- PiggyBac-mediated Cancer Immunotherapy Using EBV-specific Cytotoxic T-cells Expressing HER2-specific Chimeric Antigen ReceptorMolecular Therapy, 2011
- T Cells Targeting Carcinoembryonic Antigen Can Mediate Regression of Metastatic Colorectal Cancer but Induce Severe Transient ColitisMolecular Therapy, 2011
- piggyBac Transposon/Transposase System to Generate CD19-Specific T Cells for the Treatment of B-Lineage MalignanciesHuman Gene Therapy, 2010
- A Transposon and Transposase System for Human ApplicationMolecular Therapy, 2010
- Progress and prospects: immune responses to viral vectorsGene Therapy, 2009
- Efficient nonviral Sleeping Beauty transposon-based TCR gene transfer to peripheral blood lymphocytes confers antigen-specific antitumor reactivityGene Therapy, 2009
- piggyBac is a flexible and highly active transposon as compared to Sleeping Beauty , Tol2 , and Mos1 in mammalian cellsProceedings of the National Academy of Sciences, 2006
- A direct comparison of two nonviral gene therapy vectors for somatic integration: in vivo evaluation of the bacteriophage integrase ϕC31 and the Sleeping Beauty transposaseMolecular Therapy, 2005